Global Transcatheter Aortic Valve Replacement (TAVR) Market, By Procedure (Transfemoral Implantation, Transapial Implantation, and Transaortic Implantation), End Users (Hospitals, Ambulatory Surgical Centers, and Others) – Industry Trends and Forecast to 2030.
Transcatheter Aortic Valve Replacement (TAVR) Market Analysis and Size
The incidence of acrochordons, or skin tags, can vary among different populations and age groups. Skin tags are relatively common, and their occurrence increases with age. While exact incidence rates are challenging, studies have reported varying prevalence rates ranging from 25% to 59% in the general population.
Data Bridge Market Research analyses that the Transcatheter Aortic Valve Replacement (TAVR) market, which was USD 2,958.07 million in 2022, would rocket up to USD 13,149.36 million by 2030, and is expected to undergo a CAGR of 20.5% during the forecast period. value. “Transfemoral Implantation” dominates the procedure segment of the Transcatheter Aortic Valve Replacement (TAVR) market owing to the growing demand for better surgical and treatment methods. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Transcatheter Aortic Valve Replacement (TAVR) Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, and Pricing in USD
|
|
Segments Covered
|
By Procedure (Transfemoral Implantation, Transapial Implantation, and Transaortic Implantation), End Users (Hospitals, Ambulatory Surgical Centers, and Others)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Saudi Arabia, U.A.E, South Africa, Egypt, Israel, rest of Middle East and Africa, Brazil, Argentina and rest of South America
|
|
Market Players Covered
|
CryoLife, Inc. (U.S.); Abbott (U.S.); Micro Interventional Devices, Inc. (U.S.); Boston Scientific Corporation (U.S.); LivaNova PLC (U.K.); Meril Life Sciences Pvt. Ltd. (India); Edwards Lifesciences Corporation (U.S.); Medtronic (Ireland); Auto Tissue Berlin GmbH (Germany); Lepu Medical Technology Co. Ltd. (China); Neovasc Inc. (Canada); TTK HealthCare (India) and JenaValve Technology, Inc. (Germany)
|
|
Market Opportunities
|
|
Market Definition
Transcatheter aortic valve implantation refers to the procedure that includes the implantation of a specially designed transcatheter aortic valve capable of regenerating the blood-pumping function of the heart’s aortic valve. The implantation of these transcatheter aortic valves in patients uses three types of approaches, including transfemoral, transaortic, and transapical.
Global Transcatheter Aortic Valve Replacement (TAVR) Market Dynamics
Drivers
- Increasing Advancements in Technology
Continuous advancements in TAVR technology have improved patient outcomes and expanded the eligible patient population. Innovations such as next-generation valve designs, delivery systems, and imaging techniques have made TAVR procedures safer and more effective.
- Increasing Demand for Minimally Invasive Techniques
TAVR offers a less invasive alternative to traditional surgical aortic valve replacement (SAVR). The minimally invasive nature of TAVR procedures leads to shorter hospital stays, quicker recovery times, and reduced post-operative complications, attracting patients and healthcare providers.
Opportunities
- Reimbursement Expansion
As the clinical evidence supporting TAVR continues to grow, there is an opportunity for expanded reimbursement policies. Broader reimbursement coverage by healthcare systems and insurance providers can increase patient access to TAVR and drive market growth.
- Expansion of Other Indications
TAVR is primarily used for high-risk or inoperable patients with severe aortic stenosis. However, there is an opportunity to expand the indications for TAVR to include intermediate and low-risk patients. Ongoing clinical trials are evaluating the safety and efficacy of TAVR in these patient populations, which could significantly expand the market.
Restraints/Challenges
- High Cost and Lack of Affordability
TAVR procedures can be expensive compared to traditional surgical aortic valve replacement (SAVR). The high cost of TAVR devices, imaging equipment, and specialized training can challenge widespread adoption, especially in regions with limited healthcare budgets or reimbursement limitations.
- Limited Access and Infrastructure
Access to TAVR procedures may be limited in certain regions due to a lack of specialized centers or healthcare infrastructure. TAVR requires advanced cardiac catheterization laboratories and multidisciplinary teams, which may not be available in all healthcare settings. Expanding access to TAVR requires investments in infrastructure and establishing specialized centers.
- Reimbursement Challenges
Reimbursement policies and TAVR procedure coverage can vary across regions and healthcare systems. Sometimes, reimbursement may be limited to specific patient populations or restricted by stringent eligibility criteria. Inadequate reimbursement can create barriers to adoption and limit patient access to TAVR.
This Transcatheter Aortic Valve Replacement (TAVR) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the transcatheter aortic valve replacement (TAVR) market contact Data Bridge Market Research for an analyst brief, our team will help you make an informed market decision to achieve market growth.
Recent Developments
- In November 2020, Boston Scientific received CE Mark approval in Europe for the next-generation LOTUS Edge Aortic Valve System
- In March 2020, Edwards Lifesciences announced the launch of the SAPIEN 3 Ultra system in the United States, offering improved outcomes for TAVR procedures
- In February 2020, Medtronic received FDA approval for the Evolut PRO+ TAVR system, which incorporates design enhancements for improved valve sealing and durability
Global Transcatheter Aortic Valve Replacement (TAVR) Market Scope
The Transcatheter Aortic Valve Replacement (TAVR) market is segmented on the basis of procedure and end-users. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Procedure
- Transfemoral Implantation
- Transapial Implantation
- Transaortic Implantation
End Users
- Hospitals
- Ambulatory Surgical Centres
- Others
Global Transcatheter Aortic Valve Replacement (TAVR) Market Regional Analysis/Insights
The global Transcatheter Aortic Valve Replacement (TAVR) market is analysed and market size insights and trends are provided by country, procedure, and end-users as referenced above.
The countries covered in the transcatheter aortic valve replacement (TAVR) market report are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Saudi Arabia, U.A.E, South Africa, Egypt, Israel, rest of Middle East and Africa, Brazil, Argentina and rest of South America.
North America dominates the Transcatheter Aortic Valve Replacement (TAVR) market because of the strong base of healthcare facilities, the strong presence of major players in the market, the extraordinary healthcare infrastructure, and the large pool of people having cardiac diseases.
Asia-Pacific is expected to witness significant growth during the forecast period of 2023 to 2030 due to the increase in government initiatives to promote healthcare, the rising health awareness among the people, and the growing demand for advanced medical technology for implants and treatment, the large population pool, and the increasing demand for quality healthcare in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends, and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
The Transcatheter Aortic Valve Replacement (TAVR) market also provides you with a detailed market analysis for every country's growth in healthcare expenditure for capital equipment, installed base of different kinds of products for the transcatheter aortic valve replacement (TAVR) market, the impact of technology using lifeline curves and changes in healthcare regulatory scenarios and their impact on the transcatheter aortic valve replacement (TAVR) market.
Competitive Landscape and Transcatheter Aortic Valve Replacement (TAVR) Market Share Analysis
The Transcatheter Aortic Valve Replacement (TAVR) market competitive landscape provides details by competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width, and breadth, application dominance. The above data points provided are only related to the companies' focus related to the transcatheter aortic valve replacement (TAVR) market.
Some of the major players operating in the Transcatheter Aortic Valve Replacement (TAVR) market are:
- CryoLife, Inc. (U.S.)
- Abbott (U.S.)
- Micro Interventional Devices, Inc. (U.S.)
- Boston Scientific Corporation (U.S.)
- LivaNova PLC (U.K.)
- Meril Life Sciences Pvt. Ltd. (India)
- Edwards Lifesciences Corporation (U.S.)
- Medtronic (Ireland)
- Auto Tissue Berlin GmbH (Germany)
- Lepu Medical Technology Co. Ltd. (China)
- Neovasc Inc. (Canada)
- TTK HealthCare (India)
- JenaValve Technology, Inc. (Germany)
SKU-